Outlook Therapeutics Inc (NASDAQ:OTLK) has a beta value of 0.57 and has seen 1.48 million shares traded in the last trading session. The company, currently valued at $60.66M, closed the last trade at $2.24 per share which meant it gained $0.18 on the day or 8.74% during that session. The OTLK stock price is -473.66% off its 52-week high price of $12.85 and 61.16% above the 52-week low of $0.87. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.43 million shares traded. The 3-month trading volume is 1.81 million shares.
The consensus among analysts is that Outlook Therapeutics Inc (OTLK) is Buy stock at the moment, with a recommendation rating of 1.40. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 5 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.96.
Outlook Therapeutics Inc (NASDAQ:OTLK) trade information
Sporting 8.74% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the OTLK stock price touched $2.24 or saw a rise of 3.86%. Year-to-date, Outlook Therapeutics Inc shares have moved 18.52%, while the 5-day performance has seen it change 31.76%. Over the past 30 days, the shares of Outlook Therapeutics Inc (NASDAQ:OTLK) have changed 24.10%. Short interest in the company has seen 4.13 million shares shorted with days to cover at 1.26.
Outlook Therapeutics Inc (OTLK) estimates and forecasts
Figures show that Outlook Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -69.40% over the past 6 months, with this year growth rate of 41.50%, compared to 16.90% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
5 have an estimated revenue figure of 702.6k for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -15.45% over the past 5 years.
OTLK Dividends
Outlook Therapeutics Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Outlook Therapeutics Inc (NASDAQ:OTLK)’s Major holders
Insiders own 35.58% of the company shares, while shares held by institutions stand at 35.63% with a share float percentage of 55.31%. Investors are also buoyed by the number of investors in a company, with Outlook Therapeutics Inc having a total of 94.0 institutions that hold shares in the company. The top two institutional holders are ROSALIND ADVISORS, INC. with over 0.45 million shares worth more than $3.32 million. As of 2024-06-30, ROSALIND ADVISORS, INC. held 3.1534% of shares outstanding.
